10 results about "Trastuzumab" patented technology

Abstract Disclosed herein are Trastuzunab-linked TLR-agonist derivative analogs that include at least one non-natural amino acid, and methods for making such non-natural amino acids and polypeptides. The Trastuzunab-linked TLR-agonist derivative analogs can include a wide range of possible functionalities, but typically have at least one oxime, carbonyl, dicarbonyl, and / or hydroxylamine group. Also disclosed herein are non-natural amino acid Trastuzumab-linked TLR-agonist derivative analogs that are further modified post-translationally, methods for effecting such modifications, and methods for purifying such Trastuzumab-linked TLR-agonist derivative analogs. Typically, the modified Trastuzunab- linked TLR-agonist derivative analogs include at least one oxime, carbonyl, dicarbonyl, and / or hydroxylamine group. Further disclosed are methods for using such non-natural amino acid Trastuzumab-linked TLR-agonist derivative analogs and modified non-natural amino acid Trastuzumab-linked TLR-agonist derivative analogs, including therapeutic, diagnostic, and other biotechnology use. Abstract 20 26 20 50 50 29 J un 2 02 6 A b s t r a c t 2 0 2 6 2 0 5 0 5 0 2 9 J u n 2 0 2 6

The invention belongs to the technical field of biological medicines, and particularly relates to a combined therapy of detrastuzumab and TCR-T in solid tumors. The invention relates to application of detrastuzumab combined with TCR-T cells in preparation of drugs for treating solid tumors. According to the present invention, based on the drug action mechanism, in combination with clinical patient specimen data and single cell sequencing analysis, a variety of cytobiology and molecular biology means are adopted, and through a variety of in-vivo and in-vitro models, the macroscopic to microscopic deep research is performed; the application of TCR-T and T-DXd in solid tumors is comprehensively and systematically researched, the research process has very strong technical comprehensiveness, and the synergistic effect of T-DXd combined with TCR-T is found from the research process. At present, T-DXd is already marketed and applied clinically, and TCR-T is proved to have better safety, so that a T-DXd and TCR-T duplex strategy has a very good clinical transformation prospect, and the combination of precision medicine and transformation medicine is reflected.

A system for treating cancer is disclosed. According to an embodiment of the present invention, the system comprises: an electric field applying device for applying an electric field for tumor treatment; and a delivery system for delivering an antibody-conjugated drug; the antibody coupling drug is selected from one of a group consisting of a group consisting of Wei Dicetuzumab, a group consisting of detrastuzumab, a group consisting of enmetrastuzumab, DP-303c, a group consisting of SHR-A1811, SYD985, a group consisting of LCB14-0110, a group consisting of BDC-1001, a group consisting of BB-1701, a group consisting of TAA013 and a group consisting of A166. According to the system provided by the embodiment of the invention, non-small cell lung cancer cell proliferation can be inhibited.

This invention relates to an immunoliposome containing tebuconazole, its preparation method, and its application in anti-breast cancer treatment. The tebuconazole immunoliposome is composed of tebuconazole coated with phospholipids and cholesterol, and modified with trastuzumab. The preparation method of the tebuconazole immunoliposome of this invention is simple and exhibits excellent anti-tumor effects. The novel tebuconazole immunoliposome can overcome the drawback of tebuconazole's non-selectivity for tumor cells, thus enhancing its anti-tumor efficacy. Furthermore, the actively targeted immunoliposome with trastuzumab as a target exhibits significant targeting in vivo, and its anti-tumor effect is significantly different from that of non-targeted liposomes. This invention provides a new avenue for the anti-tumor application of tebuconazole and is of great significance for advancing the clinical application of tebuconazole.

The application discloses a cell culture method for producing trastuzumab, which can effectively reduce the acid peak of the antibody, improve the main peak of CE-SDS of the antibody, and reduce G0F and other glycosylation modifications without changing other key quality attributes of trastuzumab by adjusting the components of the feed and the culture temperature. The culture method is simple in operation and suitable for large-scale production.

The present invention relates to an antibody-drug conjugate of formula (I) or pharmaceutically acceptable salt, solvate or stereoisomer thereof, as well as to intermediates, to pharmaceutical compositions, to methods for treating diseases or disorders and the use of said compounds as pharmaceutical products for treating diseases or disorders.

Systems and methods for producing liposomes, including control liposomes and immunoliposomes targeting breast cancer are provided. Systems and methods for treating breast cancer, using targeted immunoliposomes produced according to various methods are also disclosed herein. For example, trastuzumab-conjugated immunoliposomes may be used to deliver chemotherapeutic agents to breast cancer tissues for the treatment of breast cancer. Systems and methods for actuating liposomes using ultrasound are also disclosed, such as systems and methods for actuating trastuzumab-conjugated liposomes accumulated in breast cancer tissues for the treatment of breast cancer.

Disclosed are an rk polypeptide radiopharmaceutical targeting HER2, and a preparation method therefor. The rk polypeptide radiopharmaceutical comprises an rk polypeptide dimer and a radionuclide, wherein the radionuclide marks the rk polypeptide dimer by means of a chelating agent, the rk polypeptide dimer is a polypeptide dimer formed by connecting PKM and rk polypeptide monomers and then dimerizing two rk polypeptide monomers connected to the PKM; each rk polypeptide monomer is a D-type amino acid linear eight-membered polypeptide, and the sequence of the rk polypeptide monomer is as follows: Arg-Asn-Trp-Glu-Leu-Arg-Leu-Lys; and the PKM represents a pharmacokinetic modifying molecule. The radiopharmaceutical is used for imaging diagnosis of HER2-positive tumor patients, and medication guidance and real-time therapeutic effect monitoring of patients treated by monoclonal antibodies of the anti-cancer drug trastuzumab.

The application discloses an antibody functionalized nano delivery system MET@Fe3O4@BSA-TZ and a preparation method and application thereof. A four-iron oxide (Fe3O4) nanoparticle having a chemical dynamic therapy (CDT), a photothermal therapy (PTT) and an iron death induction capacity is prepared by using a one-step hydrothermal synthesis method as a nano carrier core, metformin (MET) capable of improving a tumor microenvironment and enhancing NK cell infiltration is loaded by physical adsorption, bovine serum albumin (BSA) is wrapped on the surface to improve biocompatibility and reduce the clearance efficiency of the body, and finally, trastuzumab (TZ) is covalently coupled and modified to realize specific targeting of Her-2 positive breast cancer cells, so that a multifunctional nano delivery system MET@Fe3O4@BSA-TZ (MFBT) is successfully constructed. In-vivo and in-vitro experiments prove that the MFBT can significantly inhibit the proliferation of drug-resistant tumors, improve the immunosuppressive microenvironment of the tumor and improve the anti-tumor treatment effect, and is safe and reliable, thereby providing a new and efficient treatment strategy for the precise treatment of Her-2 positive breast cancer.

Provided are a bispecific antibody against human HER2 / CCR4 and a use thereof. Provided is a bispecific antibody capable of simultaneously targeting an HER2 target and a CCR4 target. The bispecific antibody comprises a first antigen-binding region, a second antigen-binding region and an Fc domain, wherein the first antigen-binding region has an HER2-binding activity, the second antigen-binding region has a CCR4-binding activity, and the Fc domain is an Fc domain of a trastuzumab monoclonal antibody. The bispecific antibody can bind to HER2 with a high specificity and a high affinity, and bind to CCR4 with a high specificity and a relatively low affinity. The bispecific antibody promotes effector cells to kill tumor cells and Treg cells in the tumor microenvironment, and effectively avoids the depletion of Treg cells in the peripheral blood caused by CCR4 monoclonal antibodies, thereby having a good anti-cancer activity and a higher safety.